Literature DB >> 16506051

Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour.

Mark Beresford1, Bal Sanghera, Wai-Lup Wong, Andreas Makris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16506051     DOI： 10.1007/s00259-005-0037-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

Authors:  J Chang; T J Powles; D C Allred; S E Ashley; G M Clark; A Makris; L Assersohn; R K Gregory; C K Osborne; M Dowsett
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

2.  The long-term prognostic significance of the thymidine labelling index in breast cancer.

Authors:  M Tubiana; M H Pejovic; N Chavaudra; G Contesso; E P Malaise
Journal:  Int J Cancer       Date:  1984-04-15       Impact factor: 7.396

3.  Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labeled in vivo with bromodeoxyuridine.

Authors:  J J Going; P D Stanton; T G Cooke
Journal:  Am J Clin Pathol       Date:  1993-09       Impact factor: 2.493
  3 in total
  2 in total

Review 1.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

Review 2.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.